A New Cytotoxic Dimeric Sesquiterpene Isolated from Inula racemosa Hook. f. (Root): In Vitro and In Silico Analyses

A new dimeric sesquiterpene named disesquicin (compound 1) was isolated from Inula racemosa roots by normal-phase MPLC (Medium Pressure Liquid Chromatography), and its structure was established by using extensive spectral analysis. Compound 1, when tested on different human cancer cell lines, showed marked cytotoxic activity (IC50 (µg/mL): 5.99 (MDA-MB), 9.10 (HeLa), and 12.47 (A549)). Docking study revealed that it binds at the catalytic domain of PLK-1 and interacts with catalytic site residues Leu59, Gly60, Lys61, Gly62, Cys67, Ala80, Lys82, Leu130, Arg136, Ser137, Leu139, Glu140, Lys178, Gly180, Asn181, Phe183, and Asp194. The binding of compound 1 to PLK-1 is spontaneous in nature as evident by a free energy of—8.930 kcal mol−1, corresponding to a binding affinity of 3.54 × 106 M−1. Results showed that compound 1 exhibited cytotoxic potential that was further confirmed by in vivo investigations.


Introduction
Cancer is one of the most deplorable diseases and a prevalent cause of worldwide death. According to the World Health Organization (WHO), nearly 9.5 million people died in 2018 due to cancer (http://www.who.int/mediacentre/factsheets/fs297/en/), and the main reason for death is the reappearance of treatment-resistant cancer cells in the infected area [1]. The widely available cancer treatment choices are surgery, chemotherapy and radiation therapy, which make patients' lives miserable due to their severe side effects. Polo-like kinases (PLK) belong to Ser/Thr kinase protein family, which tightly regulates the cell cycle and other cell processes. Among PLKs, PLK-1 is the most exclusively studied enzyme as it plays a significant role in cell cycle regulation and other cellular processes such as replication, transcription, translation, p53 regulation, dynamics of microtubules, recovery of different checkpoints, cell motility, etc. [2]. It has been reported that PLK-1 is overexpressed in many cancer cells such as breast cancer, ovarian cancer, skin cancer, etc. [3][4][5]. An analysis of the PLK-1 structure revealed two major druggable sites, namely (i) kinase domain harboring ATP binding site and (ii) polo-box domain. Previous studies have established that the ATP binding site in the kinase domain is the most preferred site for drug-designing. Since not many PLK-1 inhibitors are available in the market, there is a need to identify novel inhibitors, mostly from natural sources. The bioactive compounds from plants are preferred over synthetic drugs owing to Inula racemosa roots were purchased from Universal Biotech (Gali Chashreen, Farash Khana, Chandni Chowk, India). A voucher specimen (PRL/2017/21) was stored in Phytochemistry Research Lab, Pharmacognosy Department of Jamia Hamdard, and Delhi-110062 for future reference.

Instruments
ATI Mattson genesis series Fourier transform (FT-IR) infrared spectrophotometer (Midland, Canada) was used to record IR spectra. Hewlett Packard 8452A diode array spectrophotometer (Palo Alto, CA, USA) was used to obtain UV spectra. Bruker Avance DRX 500 MHz and 125 MHz spectrometers (Billerica, MA, USA) were used to obtain 1D and 2D NMR spectra for 1 H and 13 C, respectively. Bruker Bioapex FT-MS was used to obtain the EI mass spectra.

Preparation of Methanolic Extract
Inula racemosa (roots) was cleaned, washed with water, and dried in an oven at 45 • C. The dried sample was pulverized to a coarse powder using a grinder. About 2700 g of powder was extracted in Soxhlet apparatus for 72 h with methanol (20 L). The extract was filtered and evaporated under reduced pressure at 65 • C in a rotary evaporator (Buchi India, Buchi Labortechnik AG, Flawil, Switzerland). A brownish viscous residue was obtained (762 g, 18.50% w/w yield).

Fractionation and Isolation of Phytoconstituents
The methanolic residue was suspended in water (1 L) and then fractionated with ethyl acetate. Ethyl acetate fraction further subjected to column chromatography. The ethyl acetate fraction was subjected to normal-phase MPLC. The preparative separation was carried out on an Easy Extract Purification System (Buchi Labortechnik, Flawil, Switzerland) consisting of two C-605 pump modules, a C-615 control unit, and a C-640 UV detector. The preparatory separation was carried out with a 70 × 460 mm plastic-glass column (Büchi, Switzerland) packed with silica gel Si60 (50-60 µm, Merck). Elution with hexaneethyl acetate (80:20 v/v) resulted in the isolation of compound 1.  The HeLa, MDA MB-231, and A549 cells were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich, St Louis, MO, USA) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in a completely humidified atmosphere with 95% air and 5% CO 2 at 37 • C. The exponentially growing cells were sub-cultured into 6-well or 96-well plates according to the experimental requirements. The viability of the cells was determined by the trypan blue test. The cells were counted using a cell counter (Bio Rad TC20 automated cell counter) and diluted in a medium at a density of 1 × 10 5 cells/mL to be used throughout the experiments. A stock solution of test compound 1 was prepared in DMSO (w/v) and was then diluted in cell culture medium (DMSO concentration decreased to less than 0.5% w/v to avoid its cytotoxic effect) [10] to obtain the desired concentrations for cell treatment.

Cytotoxicity Assay
A CellTitre 96 ® non-radioactive cell proliferation assay kit (Promega, Madison, WI, USA) was used following the manufacturer's instructions to analyze the cytotoxic activity of compound 1 through MTT assay. Briefly, the HeLa, MDA MB-231, and A549 cells (1 × 10 4 cells/well) were grown overnight in 96-well flat-bottom cell culture plates and were then exposed for 24 h to six different concentrations of compound 1 (40, 20, 10, 5, 2.5 and 1 µg/mL). A negative control (untreated) was also maintained for comparison. After completing the desired treatment, 15 µL of MTT reagent, provided in the kit, was added to each well and further incubated for 3 h at 37 • C. Finally, the medium with MTT solution was removed, and 200 µL of solubilization solution was added to each well and further incubated for 30 min by occasional vortexing. The optical density (OD) of each well was measured at 550 nm using a Synergy microplate reader (BioTek, Winooski, VA, USA).
Results were generated from three independent experiments, and each experiment was performed in triplicate. The percentage of cytotoxicity compared to the untreated cells was estimated to determine the IC 50 value (the concentration at which 50% cell proliferation is inhibited).

Molecular Docking and Molecular Dynamics Simulation
The interaction between compound 1 and different kinases (MEK1, ERK2, JNK, JAK, PKA, PLK-1, and CDK2) was elucidated by performing molecular docking using Glide-2018-4 (Schrodinger, LLC, NY, USA) in extra precision (XP) mode, as described previously [11]. Briefly, the ligand structure (compound 1) was drawn in 2D sketcher, and the energy was minimized using OPLS3e forcefield. The 3D coordinates of kinases were downloaded from RCSB databank as MEK1 (PDB Id: 1S9J), ERK2 (PDB Id: 1wzy), JNK (PDB Id: 2P33), JAK (PDB Id: 4OLI), PKA (PDB Id: 6E99), PLK-1 (PDb Id: 2OWB), and CDK2 (PDB Id: 6GUE). The selection criteria for choosing the above mentioned crystal structures were (i) the structure should be solved by X-ray crystallography; NMR structures are not suitable for docking and simulation using Schrodinger suite, (ii) the resolution of structure should be <2.5 Å, (iii) the presence of a cognate ligand, which will help in the generation of a Grid file. Before molecular docking, the protein was preprocessed by adding missing hydrogen atoms, assigning bond orders, and deleting any hetero-atoms. Non-catalytic water molecules were also deleted. A fresh network of hydrogen bonds was created on the protein molecules after defining hydrogen atoms and energy of the whole system was minimized using OPLS3e force field. The dimensions of the Grid box and its location is given in Supplementary Table S1. The analysis and visualization of PLK-1-compound-1 interaction were performed in Maestro-2018-4 (Schrodinger, LLC, NY, USA). Binding affinity (K d ) of compound 1 towards proteins was determined from the docking free energy (∆G) using the following relation [12,13].
The dynamics and stability of the protein-ligand complex were estimated by performing molecular dynamics simulation for 50 ns using Desmond-2018-4 (Schrodinger, LLC, New York, NY, USA) as described previously [14,15]. Briefly, the protein-ligand complex was positioned in an orthorhombic-shaped simulation box, the boundaries of which were at least 10 Å away from the protein-ligand complex. The simulation box was solvated using TIP3P explicit water model, and the system was neutralized with counterions. Further, 150 mM NaCl was added to simulate the physiological conditions. The OPLS3e force field was employed to pre-equilibrate the system by performing an iteration of 2000 steps with a convergence criterion of 1 kcal/mol/Å. Finally, 50 ns simulation with NTP ensemble was performed at 300 K temperature and 1 bar pressure. The temperature and pressure of the system were maintained using Nose-Hoover Chain thermostat and a Matrtyna-Tobias-Klein barostate respectively [16,17]. During simulation, a 2 fs time step was set, and the energies/structures were recorded at every 10 ps in the trajectory.

Statistical Analysis
The statistical analysis of the triplicated samples (mean ± SD) was carried out by one-way analysis of variance (ANOVA) followed by Dunnett's test.

Isolation of Compound 1
Compound 1 was obtained as a cream colored amorphous powder from hexaneethyl acetate (80:20 v/v) eluents. Its FTIR spectrum exhibited absorption bands for O-H stretching (3343 cm −1 ), C=O stretching (1760 cm −1 ), C=C stretching (1653 cm −1 ) and C-H bending (1452 cm −1 ). Based on 13 C/DEPT NMR and mass spectra, the molecular weight of compound 1 was deduced to be 482 corresponding to the molecular formula C 30 H 42 O 5 of a sesquiterpene dimer ( Figure 1). The formula indicated ten double-bond equivalents, four of which were adjusted in two bicyclic frameworks, four in vinylic linkages, and the remaining two in two carboxylic functionalities. Its +ve ES-MS displayed a fragment ion peak at m/z 233 [C 15 H 21 O 2 ] + arising due to the fission of CH-O-CH linkage between two the sesquiterpenic units. The examination of 1D and 2D NMR spectra revealed thirty carbons consisting of eight quaternary, seven methine, twelve methylene, and three methyl carbons.

Isolation of Compound 1
Compound 1 was obtained as a cream colored amorphous powder from hexane-ethyl acetate (80:20 v/v) eluents. Its FTIR spectrum exhibited absorption bands for O-H stretching (3343 cm −1 ), C=O stretching (1760 cm −1 ), C=C stretching (1653 cm −1 ) and C-H bending (1452 cm −1 ). Based on 13 C/DEPT NMR and mass spectra, the molecular weight of compound 1 was deduced to be 482 corresponding to the molecular formula C30H42O5 of a sesquiterpene dimer ( Figure 1). The formula indicated ten double-bond equivalents, four of which were adjusted in two bicyclic frameworks, four in vinylic linkages, and the remaining two in two carboxylic functionalities. Its +ve ES-MS displayed a fragment ion peak at m/z 233 [C15H21O2] + arising due to the fission of CH-O-CH linkage between two the sesquiterpenic units. The examination of 1D and 2D NMR spectra revealed thirty carbons consisting of eight quaternary, seven methine, twelve methylene, and three methyl carbons.

Cytotoxic Effect of Compound 1
A variety of human cancer cell lines, i.e., cervical cancer (HeLa), breast cancer (MDA MB-231), and lung cancer (A549), were used for screening of the compound 1 by the standard method of MTT assay. A significant (p < 0.05) decrease in the cell viability was observed in all the cell line that was found to be concentration dependent ( Figure 2). The cell proliferation was inhibited to 85%, 77% and 71% in MDA MB-231, HeLa, and A549 cells, respectively, at the highest concentration of 40 µg/mL. The IC 50 (µg/mL) values estimated at 24 h post-treatment in these cells is 5.99 (MDA-MB cells), 9.10 (HeLa cells), and 12.47 (A549 cells). These data suggest that compound 1 exhibited higher cytotoxicity in breast cancer cells than the other cell lines. ard method of MTT assay. A significant (p < 0.05) decrease in the cell viability was observed in all the cell line that was found to be concentration dependent ( Figure 2). The cell proliferation was inhibited to 85%, 77% and 71% in MDA MB-231, HeLa, and A549 cells, respectively, at the highest concentration of 40 µg/mL. The IC50 (µg/mL) values estimated at 24 h post-treatment in these cells is 5.99 (MDA-MB cells), 9.10 (HeLa cells), and 12.47 (A549 cells). These data suggest that compound 1 exhibited higher cytotoxicity in breast cancer cells than the other cell lines.

Molecular Docking Analysis
In order to elucidate the cytotoxic potential of compound 1, we performed molecular docking of compound 1 against different kinases. Supplementary Table S1 represents Table S1). The complex between compound 1 and PLK-1 was chosen for further studies. PLK-1 (PDB Id: 2OWB) is solved at 2.10 Å resolution and harbors an ATP analog inhibitor (PHA680626). The chemical name of PHA680626 is 4-(4-methylpiperazin-1-yl)-N-[5-(2-thienylacetyl)-1,5-dihydropyrrolo [3,4-C]pyrazol-3-yl]benzamide. There were many crystal structures available for PLK-1, we chose 2OWB as the input structure for docking and simulation as it fulfilled the selection criteria of Schrodinger software (given in material and methods). Moreover, in our previous work, we used the same structure to identify Hesperidin as a potential inhibitor of PLK-1 [11]. It is worth mentioning that the reported crystal structure of PLK-1 harbors a T210TV mutation. The residue T210 participates in the catalytic action and hence it was mutated to V210 during crystallography to avoid the hydrolysis of cognate ligand PHA680626.

Molecular Docking Analysis
In order to elucidate the cytotoxic potential of compound 1, we performed molecular docking of compound 1 against different kinases. Supplementary Table S1 represents Table S1). The complex between compound 1 and PLK-1 was chosen for further studies. PLK-1 (PDB Id: 2OWB) is solved at 2.10 Å resolution and harbors an ATP analog inhibitor (PHA680626). The chemical name of PHA680626 is 4-(4-methylpiperazin-1-yl)-N-[5-(2-thienylacetyl)-1,5-dihydropyrrolo [3,4-C]pyrazol-3-yl]benzamide. There were many crystal structures available for PLK-1, we chose 2OWB as the input structure for docking and simulation as it fulfilled the selection criteria of Schrodinger software (given in material and methods). Moreover, in our previous work, we used the same structure to identify Hesperidin as a potential inhibitor of PLK-1 [11]. It is worth mentioning that the reported crystal structure of PLK-1 harbors a T210TV mutation. The residue T210 participates in the catalytic action and hence it was mutated to V210 during crystallography to avoid the hydrolysis of cognate ligand PHA680626.
The three-dimensional structure of PLK-1 can be categorized into a kinase domain, harboring ATP binding site, and a Polo-box domain. The ATP-binding site on the kinase domain is the most suitable site for an inhibitor to act on PLK-1. The X-ray crystal structure of PLK-1 reported by Kothe et al. [22] revealed that a non-hydrolyzable ATP analog PHA-680626 was bound at the active site of PLK-1. The cognate inhibitor (PHA-680626) interacts with Phe58, Lys82, Glu131, Arg134, and Asp194 [22]. Some hotspot residues of PLK-1 for binding an effective inhibitor were Cys67, Leu132, and Phe183. In the present study, the validity of molecular docking protocol was confirmed by re-docking the ligand present in the X-ray crystal structure of PLK-1, i.e., PHA680626, and compared the docking and crystal structure pose by calculating RMSD. We found that PHA680626 occupied a similar pose at the binding site of PLK-1 as occupied in the X-ray crystal structure. The RMSD between the docking pose and crystal structure pose was estimated to be 1.4373 Å (Supplementary Figure S7). Further, molecular docking between compound 1 and kinase domain PLK-1 has shown that the ligand occupied the ATP-binding site of PLK-1 (Figure 3). It formed two hydrogen bonds with Arg136 and nine hydrophobic interactions with Cys67, Ala80, Lys82, Leu130, Leu139, and Phe183. Some other residues such as Leu59, Gly60, Lys61, Gly62, Ser137, Glu140, Lys178, Gly180, Asn181, and Asp194 also formed van der Waals' interaction with compound 1 ( Table 2). It is interesting to note that compound 1 interacted with key and hotspot residues of PLK-1 such as Cys67, Lys82, Phe183, and Asp194, it could act as a potential inhibitor of PLK-1. The binding free energy and binding affinity of compound 1 towards PLK-1 were estimated to be −8.930 kcal mol −1 and 3.54 × 10 6 M −1, respectively. sent in the X-ray crystal structure of PLK-1, i.e., PHA680626, and compared the docking and crystal structure pose by calculating RMSD. We found that PHA680626 occupied a similar pose at the binding site of PLK-1 as occupied in the X-ray crystal structure. The RMSD between the docking pose and crystal structure pose was estimated to be 1.4373 Å (Supplementary Figure S7). Further, molecular docking between compound 1 and kinase domain PLK-1 has shown that the ligand occupied the ATP-binding site of PLK-1 ( Figure  3). It formed two hydrogen bonds with Arg136 and nine hydrophobic interactions with Cys67, Ala80, Lys82, Leu130, Leu139, and Phe183. Some other residues such as Leu59, Gly60, Lys61, Gly62, Ser137, Glu140, Lys178, Gly180, Asn181, and Asp194 also formed van der Waals' interaction with compound 1 ( Table 2). It is interesting to note that compound 1 interacted with key and hotspot residues of PLK-1 such as Cys67, Lys82, Phe183, and Asp194, it could act as a potential inhibitor of PLK-1. The binding free energy and binding affinity of compound 1 towards PLK-1 were estimated to be −8.930 kcal mol −1 and 3.54 × 10 6 M −1, respectively. For comparative analysis, the cognate ligand in the X-ray crystal structure of PLK-1, i.e., PHA-680626, was also docked to the active site of PLK-1 using the same procedure as adopted for PLK-1-compound 1 docking. The results revealed that PHA-680262 occupied a similar position at the active site of PLK-1 during molecular docking, as present in the X-ray structure. PHA-680626 formed two conventional and one carbon-hydrogen bond For comparative analysis, the cognate ligand in the X-ray crystal structure of PLK-1, i.e., PHA-680626, was also docked to the active site of PLK-1 using the same procedure as adopted for PLK-1-compound 1 docking. The results revealed that PHA-680262 occupied a similar position at the active site of PLK-1 during molecular docking, as present in the X-ray structure. PHA-680626 formed two conventional and one carbon-hydrogen bond with Leu59, Lys82, and Cys133 of PLK-1; nine hydrophobic interactions with Leu59, Ala80, Val114 Arg136, and Phe183; and one electrostatic (Pi-Cation) interaction with Phe183, and one Pi-Sulfur bond with Cys133 ( Figure 4). The residues forming van der Waals' interaction were Phe58, Gly62, Leu130, Glu131, Leu132, Arg134, Asn181, Gly193, and Asp194. The binding free energy of PHA-680626 towards PLK-1 was −10.000 kcal mol −1 , and the corresponding binding affinity is 2.16 × 10 7 M −1 ( Table 2). A 10-folds higher affinity of PHA680626 towards PLK-1 than compound 1 might be due to the formation of an electrostatic interaction and a Pi-sulfur bond. It is worthy to note that the amino acid residues of PLK-1 commonly involved in making contacts with PHA-680626 and compound 1 were Leu59, Gly62, Ala80, Lys82, Leu130, Arg136, Asn181, Phe183, and Asp194.

Analysis of RMSD and RMSF
The dynamic nature of interaction and the stability of PLK-1-compound 1 complex was assessed by carrying out molecular dynamics simulation under physiological conditions. We also performed molecular dynamcis of PLK-1-PHA680626 complex for the comparative analysis. The PLK-1-compound 1 complex's initial frame was subjected to molecular dynamics for 50 ns, and the results are presented in Figure 5. The root mean square deviation (RMSD) of a protein measures its deviation from the initial structure and accounts for protein stability during the simulation. The RMSD of PLK-1 alone for the initial 20 ns fluctuated between 0.0-2.2 Å and remained constant for the later part of the simulation ( Figure 5A). It indicated that the structure of PLK-1 was not changed significantly during the simulation. The RMSD of PLK-1-compound 1 complex was within 1.2-1.6 Å for the initial 15 ns; within 0.73-1.84 Å for 16-20 ns, and with 1.6-2.4 Å towards the end of the simulation. Similarly, the RMSD of PLK-1-PHA680626 complex was within 1.0-3.0 Å for the initial 15 ns and within 1.5-2.6 Å for 21-50 ns. It should be noted that none of the fluctuations in RMSD were more than the acceptable limit of 2.0 Å. Since, compound 1 and the positive control PHA680626 behaved similarly during the molecular dynamics simulation, we infer that compound 1 was bound tightly to PLK-1 and formed a stable complex.
Root mean square fluctuation (RMSF) of a protein gives an insight into the local conformational changes in the side chains of a protein during the simulation. RMSF of PLK-1 alone, PLK-1-PHA680626 and PLK-1-compound 1 complexes are given in Figure 5B. It is evident that the RMSF of PLK-1 and PLK-1 in complex with compound 1 coincided, assuring that the overall conformation of PLK-1 remained conserved. For comparison, the RMSF deviations of PLK-1 and PHA680626 complex is also shown. It is evident that the Nand C-terminal regions of PLK-1 fluctuated most as they are in an unbound form. Additionally, the total number of contacts formed by PLK-1 with compound 1 and PHA680626 was also enumerated ( Figure 6). The total number of contacts, in the form of hydrogen boning, hydrophobic interacts, electrostatic interactions and van der Waals' interactions, between PLK-1 and compound 1 was varying between 0-6, with an average of 3.5 contacts ( Figure 6A). Similarly, the total number of contact between PLK-1 and PHA680626 was between 1-9 throughout the simulation, with an average of 4.5 contacts ( Figure 6B). Overall, these results confirmed the formation of a stable complex between PLK-1 and compound 1.

Analysis of Structural Changes
The interaction between a ligand and protein often leads to changes in protein's secondary structural elements (SSE). Thus, a check on SSE variation during simulation is critical to overview the establishment of a stable PLK-1-compound 1 complex (Figure 7). The variation in total SSE (α-helix + β-sheet) of PLK-1 bound with compound 1 during simulation is presented in Figure 7A. We found that the total SSE of PLK-1 in complex with compound 1 was 44 % comprising 27% α-helix and 17% β-sheets, and it remained constant throughout the simulation. Additionally, the contribution of different amino acid residues in the formation of α-helices (light brown color bar) and β-sheets (teal color bar) is shown in Figure 7B. Overall, the results confirmed that PLK-1 and compound 1 complex was stable. Root mean square fluctuation (RMSF) of a protein gives an insight into the local conformational changes in the side chains of a protein during the simulation. RMSF of PLK-1 alone, PLK-1-PHA680626 and PLK-1-compound 1 complexes are given in Figure 5B. It is evident that the RMSF of PLK-1 and PLK-1 in complex with compound 1 coincided, assuring that the overall conformation of PLK-1 remained conserved. For comparison, the RMSF deviations of PLK-1 and PHA680626 complex is also shown. It is evident that the N-and C-terminal regions of PLK-1 fluctuated most as they are in an unbound form. Additionally, the total number of contacts formed by PLK-1 with compound 1 and PHA680626 was also enumerated ( Figure 6). The total number of contacts, in the form of hydrogen boning, hydrophobic interacts, electrostatic interactions and van der Waals' interactions, between PLK-1 and compound 1 was varying between 0-6, with an average of 3.5 contacts ( Figure 6A). Similarly, the total number of contact between PLK-1 and PHA680626 was between 1-9 throughout the simulation, with an average of 4.5 contacts ( Figure 6B). Overall, these results confirmed the formation of a stable complex between PLK-1 and compound 1.

Analysis of Structural Changes
The interaction between a ligand and protein often leads to changes in protein's secondary structural elements (SSE). Thus, a check on SSE variation during simulation is crit- variation in total SSE (α-helix + β-sheet) of PLK-1 bound with compound 1 during simulation is presented in Figure 7A. We found that the total SSE of PLK-1 in complex with compound 1 was 44 % comprising 27% α-helix and 17% β-sheets, and it remained constant throughout the simulation. Additionally, the contribution of different amino acid residues in the formation of α-helices (light brown color bar) and β-sheets (teal color bar) is shown in Figures 7B. Overall, the results confirmed that PLK-1 and compound 1 complex was stable. Since, the variations in rGyr, MolSA, SASA, and PSA of PLK-1-compound 1 complex were comparable to that of PLK-1 alone and PLK-1-PHA680626 complex, these results suggest that compound 1 remained inside the catalytic cavity of PLK-1 in a stable conformation.

Conclusions
This study reports the isolation of compound 1 (Disesquicin) for the first time from the roots of Inula racemosa. NMR and ES-MS spectra show that compound 1 belongs to the family of dimeric sesquiterpenes known for their anticancer and anti-inflammatory action. The anticancer activity of compound 1 by MTT assay confirmed its cytotoxic potential on three cell lines, i.e., HeLa (cervical), MDA-MB231 (breast), and A549 (lung). An insight into the cytotoxic potential of compound 1 reveals that it is more active against breast cancer cells. Here, we have employed an in silico approach to addressed our hypothesis that compound 1 could be a potential inhibitor of PLK-1, although there might be other possible targets also. An in silico molecular docking of compound 1 shows that it binds at the ATP binding cavity of PLK-1 and interacts with essential amino acid residues. Further, molecular dynamics simulation confirmed a stable PLK-1-compound 1 complex. We propose that compound 1 could serve as a scaffold to develop high affinity inhibitors of PLK-1 and need further biological studies for it to be a potential anticancer drug.

Conclusions
This study reports the isolation of compound 1 (Disesquicin) for the first time from the roots of Inula racemosa. NMR and ES-MS spectra show that compound 1 belongs to the family of dimeric sesquiterpenes known for their anticancer and anti-inflammatory action. The anticancer activity of compound 1 by MTT assay confirmed its cytotoxic potential on three cell lines, i.e., HeLa (cervical), MDA-MB231 (breast), and A549 (lung). An insight into the cytotoxic potential of compound 1 reveals that it is more active against breast cancer cells. Here, we have employed an in silico approach to addressed our hypothesis that compound 1 could be a potential inhibitor of PLK-1, although there might be other possible targets also. An in silico molecular docking of compound 1 shows that it binds at the ATP binding cavity of PLK-1 and interacts with essential amino acid residues. Further, molecular dynamics simulation confirmed a stable PLK-1-compound 1 complex. We propose that compound 1 could serve as a scaffold to develop high affinity inhibitors of PLK-1 and need further biological studies for it to be a potential anticancer drug.